R/R B-ALL Case Discussion: Managing Toxicities of Immunotherapies

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Find latest ALL videos · 200+ videos

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

10 seconds

Playback speed

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

R/R B-ALL Case Discussion: Managing Toxicities of Immunotherapies

By Cleveland Clinic Taussig Cancer Institute FEATURING Bassam Estfan, Paolo Caimi

29 views

October 3, 2024

Comments 0

Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

2.8K views

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

2.0K views

ASH 2024 Summary: Highlights in Adult ALL and Implications for Pract…

2024 ASH Annual Meeting Insights Hub

R. Cassaday

330 views

Perspectives on the Effects of Time Toxicity in Breast Cancer Treatm…

Kathryn Post

J. Hutchinson

740 views

Oncologists' Perspectives on the Effects of Time Toxicity in Cancer …

Safiya Karim

468 views

2024 Updates on Checkpoint Inhibitor Toxicities: A Nephrology Lens

Cleveland Clinic Taussig Cancer Institute

A. Mehdi

365 views

Current Recommendations on Managing GI Adverse Reactions Associated …

Alberto Zambelli

968 views

New

Revumenib for KMT2A+ R/R Acute Leukemias - Drug Overview and Clinica…

OncoPharm

J. Bossaer

18 views

Managing Hyperglycemia During Inavolisib Therapy: Guidelines, Patien…

Doina Catrinoiu

186 views

ASH 2024 Summary: Highlights in Ph+ ALL

2024 ASH Annual Meeting Insights Hub

F. Haddad

112 views

Managing Dermatologic Toxicities: Cutaneous irAEs Associated with Im…

Cleveland Clinic Taussig Cancer Institute

R. Unwala

295 views

Infectious Complications of Checkpoint Inhibitors: Discussing Overla…

Cleveland Clinic Taussig Cancer Institute

Z. Yetmar

231 views

Managing Inavolisib-Related Stomatitis in HR+/HER2- mBC: Dexamethaso…

OncoPharm

J. Bossaer

99 views

ALL in Adults: Overview and Recent Advances

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Cassaday

253 views

Systemic Therapies for Melanoma and Immune Related Adverse Effects (…

Melanoma Research Foundation

S. Chandra

83 views

Prevention and Management of Post-SCT Relapse in Acute Leukemias

Vanderbilt University Medical Center (VUMC)

A. Jallouk

284 views

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

974 views

Incorporation of Targeted and Immunotherapies in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

234 views

New

The Importance of Effective Patient Communication in Optimizing PARP…

Michael Friedlander

56 views

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Fred Hutchinson Cancer Center

R. Cassaday

552 views

AUTOPLAY

Login

Login

Join VuMedi

R/R B-ALL Case Discussion: Managing Toxicities of Immunotherapies

Related Videos

Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

ASH 2024 Summary: Highlights in Adult ALL and Implications for Pract…

Perspectives on the Effects of Time Toxicity in Breast Cancer Treatm…

Oncologists' Perspectives on the Effects of Time Toxicity in Cancer …

2024 Updates on Checkpoint Inhibitor Toxicities: A Nephrology Lens

Current Recommendations on Managing GI Adverse Reactions Associated …

Revumenib for KMT2A+ R/R Acute Leukemias - Drug Overview and Clinica…

Managing Hyperglycemia During Inavolisib Therapy: Guidelines, Patien…

ASH 2024 Summary: Highlights in Ph+ ALL

Managing Dermatologic Toxicities: Cutaneous irAEs Associated with Im…

Infectious Complications of Checkpoint Inhibitors: Discussing Overla…

Managing Inavolisib-Related Stomatitis in HR+/HER2- mBC: Dexamethaso…

ALL in Adults: Overview and Recent Advances

Systemic Therapies for Melanoma and Immune Related Adverse Effects (…

Prevention and Management of Post-SCT Relapse in Acute Leukemias

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Incorporation of Targeted and Immunotherapies in ALL

The Importance of Effective Patient Communication in Optimizing PARP…

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …